BCR-ABL1 Kinase Domain Mutation (IRMA) by NGS

Utilizes next-generation sequencing (NGS) to identify mutations in the BCR-ABL kinase domain, which can impact the treatment of chronic myelogenous leukemia (CML). It informs treatment strategies.

Also known asBcr-abl Kinase Domain Mutation Analysis By Ngs Bcr-abl Kinase Domain Mutation Analysis By Ngs

Available via

Home Collection, Lab Visit

Contains

1 parameters

Earliest reports in

17 Working Days

Test details
Preparations

No special preparations needed

Test included
BCR-ABL1 Kinase Domain Mutation (IRMA) by NGS includes 1 parameter

  • Specimen

Test code

G635

Specimen vol. and vacutainer information
SpecimenVacutainerVolume
Edta Whole BloodLavender Vacutainer3 ML

Specimen stability information

Edta Whole Blood

Specimen rejection criteria

Test run frequency

Every Day TIME - 10:00

Turn around time

17 Working Days

Performing locations

Department

  • Advanced Molecular Diagnostics R&d

CPT and Loinc codes

BCR-ABL1 Kinase Domain Mutation (IRMA) by NGS

11000